Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer

BACKGROUND: The early identification of treatment effect is wanted in several settings, including the management of metastatic colorectal cancer (mCRC). A potential universal marker is circulating tumor DNA (ctDNA). Our prospective study explored the association between progression-free survival (PF...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomsen, Caroline B., Hansen, Torben F., Andersen, Rikke F., Lindebjerg, Jan, Jensen, Lars H., Jakobsen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252368/
https://www.ncbi.nlm.nih.gov/pubmed/32518596
http://dx.doi.org/10.1177/1758835920918472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252368/
https://www.ncbi.nlm.nih.gov/pubmed/32518596
http://dx.doi.org/10.1177/1758835920918472

Ejemplares similares